



***Thomas P. Monath, MD**

Biography:

Dr. Thomas P. Monath, a physician, is a consultant to the biotechnology industry. He is currently Chief Scientific and Chief Operations Officer of Newlink Genetics Corporation's wholly-owned subsidiary, BioProtection Systems Corp. and is helping determine if the Canadian/NewLink Ebola vaccine candidate will provide part of the solution to one of the world's biggest public health challenges. He was formerly Chief Medical Officer of Hookipa BioTech AG and Chief Technical Officer of PaxVax Inc, where he was also engaged in development of new vaccines. His expertise and experience cut across discovery research, process and analytical development, manufacturing, preclinical and clinical development, and regulatory affairs. Monath is also a Venture Partner at Kleiner Perkins Caufield & Byers and is a Director of Sentinext plc, Rapid MicroBiosystems Inc, and U.S. Biologics Inc.

Between 1992-2012 he was Adjunct Professor, Harvard School of Public Health. Between 1992 and 2006. Dr. Monath was Chief Scientific Officer and an Executive Director, Acambis plc (a publicly traded biopharmaceutical company recently acquired by Sanofi Pasteur) where he pioneered the development of ChimeriVax® vaccines against dengue, West Nile, and Japanese encephalitis (using yellow fever as a live vector), vaccines against yellow fever, Clostridium difficile, and Helicobacter pylori, as well as a cell based smallpox vaccine, ACAM2000 which has now replaced calf lymph vaccine in the US national stockpile. The JE vaccine (IMOJEV®) is licensed in multiple countries; the West Nile vaccine (Prevenile®) is licensed for use in horses; and the dengue and C. difficile vaccines are in Phase III trials.

Dr. Monath received his undergraduate and M.D. degrees from Harvard and trained in internal medicine at the Peter Bent Brigham Hospital, Boston. COL Monath retired from the US Army in 1992 after 24 years in the uniformed services (Army and U.S. Public Health Service). Between 1973-1988, he was Director, Division of Vector-Borne Viral Diseases, U. S. Centers for Disease Control (CDC), Fort Collins CO and from 1989-92 Chief, Virology Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). He has worked overseas in Nigeria, Sierra Leone, Cameroun, Argentina, Ecuador and elsewhere doing field research on arboviruses and hemorrhagic fevers. In 1972, he discovered the rodent reservoir of Lassa fever virus. He is on the editorial board of 5 scientific journals.

He received the Nathaniel A. Young Award (1984), the Richard M. Taylor Award (1996), and the Walter Reed Medal (2002) from the American Society of Tropical Medicine & Hygiene and was President of that Society (2004-05). He has served on numerous government and international committees on infectious diseases, biosecurity, World Health Organization expert committees and the National Vaccines Advisory Committee (USA). From 1998-2000, Monath was Senior Science advisor to the Director, Central Intelligence Agency. Dr. Monath has published 400 papers and 6 books on the epidemiology, immunology and pathogenesis of arboviruses and on vaccine development.

A leader in the "One Health" movement, Dr. Monath served on the American Veterinary Medical Association's "One Health" Task Force and subsequently the One Health Commission (USA). He currently co-manages the One Health Initiative website <http://www.onehealthinitiative.com> with Laura H. Kahn, MD, MPH, MPP, Bruce Kaplan, DVM, Jack Woodall, PhD and Lisa A. Conti, DVM, MPH. Dr. Monath co-edited a unique 'first of its kind' One Health monograph in the Veterinaria Italiana Journal's 2009 - Volume 45 (1), January-March http://www.izs.it/vet_italiana/2009/45_1/45_1.htm with Drs. Kahn and Kaplan. They also co-authored the introductory chapter to the 2010 One Health book "Human-Animal Medicine – *Clinical Approaches to Zoonoses, Toxicants and other Shared Health Risks*" <http://www.us.elsevierhealth.com/product.jsp?isbn=9781416068372> and co-edited the 2014 One Health book "*Confronting Emerging Zoonoses – The One Health Paradigm*" <http://www.springer.com/978-4-431-55119-5> with Akio Yamada, DVM, PhD and the One Health Initiative team.